Contribution of APOA5, APOC3, CETP, ABCA1 and SIK3 genetic variants to hypertriglyceridemia development in Mexican HIV-patients receiving antiretroviral therapy

Bautista-Martínez, Jonathan Saúl; Mata‐Marín, José Antonio; Sandoval-Ramírez, Jorge Luis; Chaparro-Sánchez, Alberto; Manjarrez-Tellez, Bulmaro; Uribe-Noguez, Luis Antonio; Gaytán-Martı́nez, Jesús; Núñez-Armendáriz, Mireya; Cruz-Sánchez, Arcenio; Nuñez-Rodríguez, Nohemí; Iván, Martínez-Abarca; Morales-González, Georgina Selene; Alvarez-Mendoza, J P; Pérez-Barragán, Edgar; Ríos, Jussara Ríos-De Los; Contreras-Chávez, Gerson Gabriel; Tapia-Magallanes, Denisse Marielle; Ribas‐Aparicio, Rosa María; Díaz-López, Mónica; Olivares-Labastida, Azucena; Gómez‐Delgado, Alejandro; Torres, Javier; Miranda‐Duarte, Antonio; Zenteno, Juan Carlos; Pompa-Mera, Ericka N.

doi:10.1097/fpc.0000000000000458

Cited by 2 publications

(1 citation statement)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ESR1 and ESR2 genes were both associated with body mass index (BMI) and total subcutaneous fat, while ESR2 also conferred risk for lipoatrophy in women undergoing PI-containing regimens ( Gasparotto et al , 2012 ). SNPs at APOA5 , APOC3 and SIK3 were also implicated in risk of hypertriglyceridemia in a case-control study including 602 Mexicans patients receiving PIs ( Bautista-Martínez et al , 2022 ).…”

Section: Metabolism Enzymes and Related Transcription Factorsmentioning

confidence: 99%

Pharmacogenetics of HIV therapy: State of the art in Latin American countries

et al. 2022

View full text Add to dashboard Cite

The use of combined antiretroviral therapy (cART) has resulted in a remarkable reduction in morbidity and mortality of people living with HIV worldwide. Nevertheless, interindividual variations in drug response often impose a challenge to cART effectiveness. Although personalized therapeutic regimens may help overcome incidence of adverse reactions and therapeutic failure attributed to host factors, pharmacogenetic studies are often restricted to a few populations. Latin American countries accounted for 2.1 million people living with HIV and 1.4 million undergoing cART in 2020-21. The present review describes the state of art of HIV pharmacogenetics in this region and highlights that such analyses remain to be given the required relevance. A broad analysis of pharmacogenetic markers in Latin America could not only provide a better understanding of genetic structure of these populations, but might also be crucial to develop more informative dosing algorithms, applicable to non-European populations.

show abstract

Section: Metabolism Enzymes and Related Transcription Factorsmentioning

confidence: 99%